Key terms
About PTGX
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PTGX news
Mar 18
7:10am ET
Protagonist closes rusfertide license, collaboration agreement with Takeda
Mar 11
12:05pm ET
Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113
Mar 11
8:41am ET
Protagonist Therapeutics announces presentation of data on JNJ-2113
Mar 11
12:25am ET
Strong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlook
Feb 29
1:02am ET
New Debt & Financing Risk for Protagonist Therapeutics Inc – What’s the Latest?
Feb 28
8:40am ET
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Progyny (PGNY) and Protagonist Therapeutics (PTGX)
Feb 28
7:10am ET
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)
Feb 28
7:06am ET
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Feb 28
12:40am ET
Analysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)
Feb 09
10:16am ET
Protagonist Therapeutics Earns ‘Buy’ Rating: Promising Clinical Advances and Strategic Partnerships
Feb 01
11:49pm ET
3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
Feb 01
8:19pm ET
Buy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide’s Market Potential
Feb 01
12:00pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 01
6:47am ET
Buy Rating Affirmed for Protagonist Therapeutics Following Strategic Takeda Collaboration and Promising Drug Pipeline
Feb 01
6:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and Protagonist Therapeutics (PTGX)
Jan 31
6:41pm ET
Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide
Jan 29
3:20am ET
3 Best Stocks to Buy Now, 1/29/2024, According to Top Analysts
Jan 26
12:25am ET
Buy Rating on Protagonist Therapeutics: Anticipating Rusfertide Success and Strategic Acquisition Upside
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
9:03am ET
Capital One reveals top six biotech picks for 2024
Jan 07
5:39am ET
BTIG Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
Jan 02
9:46am ET
BTIG Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
Dec 31
5:23am ET
BTIG Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
No recent press releases are available for PTGX
PTGX Financials
Key terms
Ad Feedback
PTGX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PTGX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
